Cutia Therapeutics (2487) Stock Statistics & Valuation Metrics

Cutia Therapeutics has a market cap or net worth of HK$385.77M. The enterprise value is HK$621.20M.

Cutia Therapeutics has 374,533,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cutia Therapeutics’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -25.31%.

The current PE Ratio of Cutia Therapeutics is ―. Cutia Therapeutics’s PEG ratio is 0.15.

In the last 12 months, Cutia Therapeutics had revenue of 336.15M and earned -340.19M in profits. Earnings per share was -1.03.

In the last 12 months, operating cash flow was -226.70M and capital expenditures -4.75M, giving a free cash flow of -231.46M billion.

Cutia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Cutia Therapeutics upcoming earnings date is Mar 30, 2027, Before Open (Confirmed).

Cutia Therapeutics as a current ratio of 3.87, with Debt / Equity ratio of 38.53%

In the past 12 months, Cutia Therapeutics has paid 0.00 in taxes.

Cutia Therapeutics EV to EBITDA ratio is -5.04, with an EV/FCF ratio of -4.62.

Cutia Therapeutics has HK$626.38M in cash and marketable securities with HK$274.17M in debt, giving a net cash position of HK$352.21M billion.

Gross margin is 53.59%, with operating margin of -91.81%, and net profit margin of -101.20%.

The average price target for Cutia Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―